MedTrace Logo

Beta Blocker for Chronic Wound Healing

NCT00368602 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2015-04-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of treatment of chronic cutaneous ulcers and burn wounds with topical beta adrenergic antagonists (Timoptic®).

Conditions

  • Ulcer
  • Burns

Interventions

DRUG

Timoptic

Timoptic to be applied to the target wound daily for up to 12 weeks.

OTHER

Placebo

Saline solution with no active ingredients to be applied to the target wound daily for up to 12 weeks.

Sponsors & Collaborators

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Rivkah R Isseroff, MD · University of California, Davis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00368602 on ClinicalTrials.gov